Sagimet Biosciences (SGMT) EBITDA (2022 - 2026)

Sagimet Biosciences' EBITDA history runs 5 years deep, the most recent figure standing at -$11.7 million for Q1 2026.

• On a quarterly basis, EBITDA rose 41.04% year-over-year to -$11.7 million in Q1 2026; TTM through Mar 2026 was -$48.7 million, a 25.65% increase from a year earlier, with the FY2025 full-year figure at -$56.9 million, down 4.47% from the prior year.
• EBITDA declined to -$11.7 million in Q1 2026 per SGMT's latest filing, from -$10.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$6.8 million in Q1 2023 and bottomed at -$19.9 million in Q1 2025.
• The 5-year median for EBITDA is -$10.0 million (2023), against an average of -$11.0 million.
• Across the five-year window, EBITDA tumbled 126.81% in 2024 and soared 41.04% in 2026, its largest moves.
• Year by year, EBITDA stood at -$7.4 million in 2022, then fell by 28.13% to -$9.5 million in 2023, then plunged by 92.21% to -$18.2 million in 2024, then jumped by 40.84% to -$10.8 million in 2025, then retreated by 8.81% to -$11.7 million in 2026.
• Per Business Quant, the three latest SGMT EBITDA figures stand at -$11.7 million (Q1 2026), -$10.8 million (Q4 2025), and -$14.3 million (Q3 2025).